{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:28:15Z","timestamp":1787318895775,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,24]]},"DOI":"10.7759\/cureus.86701","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:46:57Z","timestamp":1750812417000},"source":"Crossref","is-referenced-by-count":2,"title":["Methylene Blue in Septic Shock: Emerging Evidence, Clinical Applications, and Future Directions"],"prefix":"10.7759","author":[{"given":"Namrata","family":"Maheshwari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Malkania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasil","family":"Mudiyanselage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer M","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al.. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016, 315:801-10. 10.1001\/jama.2016.0287","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd KE","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, et al.. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020, 395:200-11. 10.1016\/S0140-6736(19)32989-7","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"49","author":"Evans L","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, et al.. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021, 49:e1063-143. 10.1097\/CCM.0000000000005337","journal-title":"Crit Care Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208623","article-title":"Severe sepsis and septic shock","volume":"369","author":"Angus DC","year":"2013","unstructured":"Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013, 369:840-51. 10.1056\/NEJMra1208623","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-019-0498-7","article-title":"Current use of vasopressors in septic shock","volume":"9","author":"Scheeren TW","year":"2019","unstructured":"Scheeren TW, Bakker J, De Backer D, et al.. Current use of vasopressors in septic shock. Ann Intensive Care. 2019, 9:20. 10.1186\/s13613-019-0498-7","journal-title":"Ann Intensive Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093188","article-title":"2023 update on sepsis and septic shock in adult patients: management in the emergency department","volume":"12","author":"Guarino M","year":"2023","unstructured":"Guarino M, Perna B, Cesaro AE, Maritati M, Spampinato MD, Contini C, De Giorgio R. 2023 update on sepsis and septic shock in adult patients: management in the emergency department. J Clin Med. 2023, 12:3188. 10.3390\/jcm12093188","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0885066609340519","article-title":"Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress","volume":"24","author":"D\u00fcnser MW","year":"2009","unstructured":"D\u00fcnser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med. 2009, 24:293-316. 10.1177\/0885066609340519","journal-title":"J Intensive Care Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0862CP","article-title":"Potentially inadvertent immunomodulation: norepinephrine use in sepsis","volume":"194","author":"Stolk RF","year":"2016","unstructured":"Stolk RF, van der Poll T, Angus DC, van der Hoeven JG, Pickkers P, Kox M. Potentially inadvertent immunomodulation: norepinephrine use in sepsis. Am J Respir Crit Care Med. 2016, 194:550-8. 10.1164\/rccm.201604-0862CP","journal-title":"Am J Respir Crit Care Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes A","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, et al.. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017, 43:304-77. 10.1007\/s00134-017-4683-6","journal-title":"Intensive Care Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock","volume":"377","author":"Khanna A","year":"2017","unstructured":"Khanna A, English SW, Wang XS, et al.. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017, 377:419-30. 10.1056\/NEJMoa1704154","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705716","article-title":"Hydrocortisone plus fludrocortisone for adults with septic shock","volume":"378","author":"Annane D","year":"2018","unstructured":"Annane D, Renault A, Brun-Buisson C, et al.. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018, 378:809-18. 10.1056\/NEJMoa1705716","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04190-y","article-title":"Microcirculatory alterations in critically ill COVID-19 patients analyzed using artificial intelligence","volume":"26","author":"Hilty MP","year":"2022","unstructured":"Hilty MP, Favaron E, Wendel Garcia PD, et al.. Microcirculatory alterations in critically ill COVID-19 patients analyzed using artificial intelligence. Crit Care. 2022, 26:311. 10.1186\/s13054-022-04190-y","journal-title":"Crit Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.04.034","article-title":"Methylene blue and Alzheimer's disease","volume":"78","author":"Oz M","year":"2009","unstructured":"Oz M, Lorke DE, Petroianu GA. Methylene blue and Alzheimer's disease. Biochem Pharmacol. 2009, 78:927-32. 10.1016\/j.bcp.2009.04.034","journal-title":"Biochem Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000124","article-title":"Pharmacokinetics and organ distribution of intravenous and oral methylene blue","volume":"56","author":"Peter C","year":"2000","unstructured":"Peter C, Hongwan D, K\u00fcpfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000, 56:247-50. 10.1007\/s002280000124","journal-title":"Eur J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01422-x","article-title":"Vasopressor-sparing action of methylene blue in severe sepsis and shock: a narrative review","volume":"37","author":"Puntillo F","year":"2020","unstructured":"Puntillo F, Giglio M, Pasqualucci A, Brienza N, Paladini A, Varrassi G. Vasopressor-sparing action of methylene blue in severe sepsis and shock: a narrative review. Adv Ther. 2020, 37:3692-706. 10.1007\/s12325-020-01422-x","journal-title":"Adv Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2005.07.011","article-title":"Vasoplegic syndrome--the role of methylene blue","volume":"28","author":"Shanmugam G","year":"2005","unstructured":"Shanmugam G. Vasoplegic syndrome--the role of methylene blue. Eur J Cardiothorac Surg. 2005, 28:705-10. 10.1016\/j.ejcts.2005.07.011","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0563-x","article-title":"High absolute bioavailability of methylene blue given as an aqueous oral formulation","volume":"65","author":"Walter-Sack I","year":"2009","unstructured":"Walter-Sack I, Rengelshausen J, Oberwittler H, Burhenne J, Mueller O, Meissner P, Mikus G. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol. 2009, 65:179-89. 10.1007\/s00228-008-0563-x","journal-title":"Eur J Clin Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/anae.15185","article-title":"Education and scientific dissemination during the COVID-19 pandemic","volume":"76","author":"Fawcett WJ","year":"2021","unstructured":"Fawcett WJ, Charlesworth M, Cook TM, Klein AA. Education and scientific dissemination during the COVID-19 pandemic. Anaesthesia. 2021, 76:301-4. 10.1111\/anae.15185","journal-title":"Anaesthesia"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600610710","article-title":"Pharmacokinetics of highly ionized drugs. II. Methylene blue--absorption, metabolism, and excretion in man and dog after oral administration","volume":"61","author":"DiSanto AR","year":"1972","unstructured":"DiSanto AR, Wagner JG. Pharmacokinetics of highly ionized drugs. II. Methylene blue--absorption, metabolism, and excretion in man and dog after oral administration. J Pharm Sci. 1972, 61:1086-90. 10.1002\/jps.2600610710","journal-title":"J Pharm Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/ni1001-907","article-title":"Nitric oxide and the immune response","volume":"2","author":"Bogdan C","year":"2001","unstructured":"Bogdan C. Nitric oxide and the immune response. Nat Immunol. 2001, 2:907-16. 10.1038\/ni1001-907","journal-title":"Nat Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2003.152","article-title":"Regulation of the expression of inducible nitric oxide synthase","volume":"384","author":"Kleinert H","year":"2003","unstructured":"Kleinert H, Schwarz PM, F\u00f6rstermann U. Regulation of the expression of inducible nitric oxide synthase. Biol Chem. 2003, 384:1343-64. 10.1515\/BC.2003.152","journal-title":"Biol Chem"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.002907","article-title":"cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action","volume":"62","author":"Francis SH","year":"2010","unstructured":"Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010, 62:525-63. 10.1124\/pr.110.002907","journal-title":"Pharmacol Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-013-0298-7","article-title":"Methylene blue for distributive shock: a potential new use of an old antidote","volume":"9","author":"Jang DH","year":"2013","unstructured":"Jang DH, Nelson LS, Hoffman RS. Methylene blue for distributive shock: a potential new use of an old antidote. J Med Toxicol. 2013, 9:242-9. 10.1007\/s13181-013-0298-7","journal-title":"J Med Toxicol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90072-5","article-title":"Inhibition of nitric oxide synthesis by methylene blue","volume":"45","author":"Mayer B","year":"1993","unstructured":"Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol. 1993, 45:367-74. 10.1016\/0006-2952(93)90072-5","journal-title":"Biochem Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1590\/s0102-76382009000400005","article-title":"Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties","volume":"24","author":"Evora PR","year":"2009","unstructured":"Evora PR, Ribeiro PJ, Vicente WV, et al.. Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties. Rev Bras Cir Cardiovasc. 2009, 24:279-88. 10.1590\/s0102-76382009000400005","journal-title":"Rev Bras Cir Cardiovasc"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/0885066606290671","article-title":"Use of methylene blue in sepsis: a systematic review","volume":"21","author":"Kwok ES","year":"2006","unstructured":"Kwok ES, Howes D. Use of methylene blue in sepsis: a systematic review. J Intensive Care Med. 2006, 21:359-63. 10.1177\/0885066606290671","journal-title":"J Intensive Care Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(91)90311-r","article-title":"Methylene blue as an inhibitor of superoxide generation by xanthine oxidase: a potential new drug for the attenuation of ischemia\/reperfusion injury","volume":"42","author":"Salaris SC","year":"1991","unstructured":"Salaris SC, Babbs CF, Voorhees WD 3rd. Methylene blue as an inhibitor of superoxide generation by xanthine oxidase: a potential new drug for the attenuation of ischemia\/reperfusion injury. Biochem Pharmacol. 1991, 42:499-506. 10.1016\/0006-2952(91)90311-r","journal-title":"Biochem Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199502000-00010","article-title":"Methylene blue administration in septic shock: a clinical trial","volume":"23","author":"Preiser JC","year":"1995","unstructured":"Preiser JC, Lejeune P, Roman A, et al.. Methylene blue administration in septic shock: a clinical trial. Crit Care Med. 1995, 23:259-64. 10.1097\/00003246-199502000-00010","journal-title":"Crit Care Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200110000-00002","article-title":"Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study","volume":"29","author":"Kirov MY","year":"2001","unstructured":"Kirov MY, Evgenov OV, Evgenov NV, et al.. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. 2001, 29:1860-7. 10.1097\/00003246-200110000-00002","journal-title":"Crit Care Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X0203000606","article-title":"The influence of methylene blue infusion on cytokine levels during severe sepsis","volume":"30","author":"Memis D","year":"2002","unstructured":"Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care. 2002, 30:755-62. 10.1177\/0310057X0203000606","journal-title":"Anaesth Intensive Care"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04397-7","article-title":"Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial","volume":"27","author":"Ibarra-Estrada M","year":"2023","unstructured":"Ibarra-Estrada M, Kattan E, Aguilera-Gonz\u00e1lez P, et al.. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care. 2023, 27:110. 10.1186\/s13054-023-04397-7","journal-title":"Crit Care"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-024-02792-3","article-title":"Comparative study between high and low dose methylene blue infusion in septic cancer patients: a randomized, blinded, controlled study","volume":"25","author":"Shaker EH","year":"2025","unstructured":"Shaker EH, Soliman AM, Bedewy AA, Elrawas MM. Comparative study between high and low dose methylene blue infusion in septic cancer patients: a randomized, blinded, controlled study. BMC Anesthesiol. 2025, 25:15. 10.1186\/s12871-024-02792-3","journal-title":"BMC Anesthesiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.21037\/jeccm-22-95","article-title":"A case series of slow continuous ultrafiltration for COVID-19 patients on extracorporeal membrane oxygenation","volume":"7","author":"Kannan L","year":"2023","unstructured":"Kannan L, Syeda U. A case series of slow continuous ultrafiltration for COVID-19 patients on extracorporeal membrane oxygenation. J Emerg Crit Care Med. 2023, 7:10.21037\/jeccm-22-95","journal-title":"J Emerg Crit Care Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10071-24905","article-title":"Effects of early use of methylene blue and vasopressin on noradrenaline dose in septic shock: a randomized controlled trial","volume":"29","author":"Kuri HR","year":"2025","unstructured":"Kuri HR, Sharma A, Meshram T, et al.. Effects of early use of methylene blue and vasopressin on noradrenaline dose in septic shock: a randomized controlled trial. Indian J Crit Care Med. 2025, 29:108-12. 10.5005\/jp-journals-10071-24905","journal-title":"Indian J Crit Care Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000001110","article-title":"Methylene blue in septic shock: a systematic review and meta-analysis","volume":"6","author":"Fernando SM","year":"2024","unstructured":"Fernando SM, Tran A, Soliman K, et al.. Methylene blue in septic shock: a systematic review and meta-analysis. Crit Care Explor. 2024, 6:e1110. 10.1097\/CCE.0000000000001110","journal-title":"Crit Care Explor"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2023.09.037","article-title":"Methylene blue reduces mortality in critically ill and perioperative patients: a meta-analysis of randomized trials","volume":"38","author":"Pruna A","year":"2024","unstructured":"Pruna A, Bonaccorso A, Belletti A, et al.. Methylene blue reduces mortality in critically ill and perioperative patients: a meta-analysis of randomized trials. J Cardiothorac Vasc Anesth. 2024, 38:268-74. 10.1053\/j.jvca.2023.09.037","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04615-2","article-title":"Methylene blue as adjunctive therapy in septic shock: correct drug diluent derives optimal efficacy","volume":"27","author":"Dubey D","year":"2023","unstructured":"Dubey D, Ray P, Imran A. Methylene blue as adjunctive therapy in septic shock: correct drug diluent derives optimal efficacy. Crit Care. 2023, 27:337. 10.1186\/s13054-023-04615-2","journal-title":"Crit Care"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318169167f","article-title":"Vasoactive drugs and acute kidney injury","volume":"36","author":"Bellomo R","year":"2008","unstructured":"Bellomo R, Wan L, May C. Vasoactive drugs and acute kidney injury. Crit Care Med. 2008, 36:S179-86. 10.1097\/CCM.0b013e318169167f","journal-title":"Crit Care Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2013.02.026","article-title":"Methylene blue is associated with poor outcomes in vasoplegic shock","volume":"27","author":"Weiner MM","year":"2013","unstructured":"Weiner MM, Lin HM, Danforth D, Rao S, Hosseinian L, Fischer GW. Methylene blue is associated with poor outcomes in vasoplegic shock. J Cardiothorac Vasc Anesth. 2013, 27:1233-8. 10.1053\/j.jvca.2013.02.026","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32836498f4","article-title":"PharmGKB summary: methylene blue pathway","volume":"23","author":"McDonagh EM","year":"2013","unstructured":"McDonagh EM, Bautista JM, Youngster I, Altman RB, Klein TE. PharmGKB summary: methylene blue pathway. Pharmacogenet Genomics. 2013, 23:498-508. 10.1097\/FPC.0b013e32836498f4","journal-title":"Pharmacogenet Genomics"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109359098","article-title":"CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity","volume":"25","author":"Gillman PK","year":"2011","unstructured":"Gillman PK. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol. 2011, 25:429-36. 10.1177\/0269881109359098","journal-title":"J Psychopharmacol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(03)01510-8","article-title":"Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery","volume":"77","author":"Levin RL","year":"2004","unstructured":"Levin RL, Degrange MA, Bruno GF, et al.. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004, 77:496-9. 10.1016\/S0003-4975(03)01510-8","journal-title":"Ann Thorac Surg"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129305","article-title":"Vasopressors for the treatment of septic shock: systematic review and meta-analysis","volume":"10","author":"Avni T","year":"2015","unstructured":"Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One. 2015, 10:e0129305. 10.1371\/journal.pone.0129305","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2478-6","article-title":"Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis","volume":"23","author":"Vincent JL","year":"2019","unstructured":"Vincent JL, Jones G, David S, Olariu E, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care. 2019, 23:196. 10.1186\/s13054-019-2478-6","journal-title":"Crit Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/369370-methylene-blue-in-septic-shock-emerging-evidence-clinical-applications-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:46:58Z","timestamp":1750812418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/369370-methylene-blue-in-septic-shock-emerging-evidence-clinical-applications-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.86701","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}